60033-23-0

Upstream product

• 624-92-0 Dimethyldisulphide 
• 505-73-7 disulfanediyldiacetic acid 
• 2949-92-0 methanethiosulfonic acid S-methyl ester 
• 68-11-1 mercaptoacetic acid 
• 75-18-3 dimethylsulfide 
• 5813-48-9 Methanesulfenyl chloride 

Downstream Products

• 485801-41-0 C₅₉H₉₃NO₁₅S₂Si₂ 

Relevant academic research and scientific papers

Synthesis of S-thiomethyl MAG3, radiolabelling with technetium-99m and biological evaluation

Protection of the thiolate function of the mercaptoacetyltriglycine (MAG3) by S-thiomethyl group allows automatic deprotection of the protecting group during technetium-99m radiolabelling by transchelation using stannous chloride dihydrate as r

Semisynthetic Maytansine analogues for the targeted treatment of cancer

Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells. A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized. The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied. Several of these maytansinoids were found to be even more potent in vitro than maytansine. The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.

SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS

This invention provides compounds of formula (1) wherein X is C3-7 cycloalkyl, pyridinyl, pyrimidinyl or phenyl ring optionally substituted as described in claim 1, R1, R3 and R4 are chosen from the groups listed in claim 1. R2 is chosen from various unsaturated acyl groups listed in claim 1, with certain compounds being disclaimed. Use as tyrosine kinase inhibitors for the treatment of cancer and certain kidney diseases such as polycystic kidney disease.

Substituted quinazoline derivatives

This invention provides compounds of formula 1 having the structure wherein: X, R1, R2, R3, R4, Z, X, and n are as defined hereinbefore in the specification, which are useful as antineoplastic agents and in the treatment of certain kidney diseases, such as polycystic kidney disease.

Cleavage of S-S bond by nitric oxide (NO) in the presence of oxygen: A disproportionation reaction of two disulfides

Disulfide bond was cleaved by a catalytic amount of nitric oxide in the presence of oxygen, which was confirmed by experiments employing two symmetrical disulfides. The reaction resulted in the formation of unsymmetrical disulfides in nearly 50% yields. The steric hindrance of alkyl disulfide slowed the reaction rate, and an electron-donating group on the aryl disulfide promoted the reaction. The substituent and S-nitrosothiol effects suggested that the reaction was initialized with an oxidative process by NO+.

7-Dithioacetamido cephalosporins

Novel cephalosporins having a dithioacetamido substituent at the 7-position are prepared. These compounds have antibacterial activity.